Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study

Fig. 2

Best percentage change from baseline in sums of diameters of target lesions. A In the RT + PD1 group based on RECIST 1.1, B In the TACE plus sorafenib group based on RECIST 1.1, C In the RT + PD1 group based on mRECIST, D In the TACE plus sorafenib group based on mRECIST. RT Radiotherapy; PD1 Monoclonal antibody against programmed cell death; TACE Transcatheter arterial chemoembolization; RECIST 1.1 Response Evaluation Criteria in Solid Tumors 1.1; mRECIST Modified Response Evaluation Criteria in Solid Tumors; CR Complete response; PR Partial response; SD Stable disease; PD Progressive disease

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us